September 15 - 16, 2011, The New York Academy of Sciences and the Global Medical Excellence Cluster (GMEC), in collaboration with Imperial College London and King's College London, will host a two-day scientific conference, "Animal Models and Their Value in Predicting Drug Efficacy and Toxicity," that will provide a forum to critically examine the role of pre-clinical animal models in drug discovery. Areas of focus include: how do animal models most effectively contribute to translational medicine and drug discovery? What changes are needed to increase the predictive power of various models for drug efficacy in humans? and what can be done to further refine, reduce, and replace animal models in biomedical research?
By convening multi-disciplinary clinical and basic science investigators, the Academy and GMEC hope to aid in identifying common hurdles to improving model systems for the evaluation of therapeutic efficacy and toxicity in the areas of metabolic and cardiovascular disease, inflammation, and pain as well as ways of moving forward. "The long-standing practice of using small and large animals to predict drug safety and efficacy in humans is costly, time-consuming, and not always reliable. By bringing together leading scientists from multiple sectors and regions to share their innovations that possess the potential to improve the prediction of drug safety and toxicity before use in patients, we are fostering the development of more reliable models and assays that may allow us to significantly reduce or eliminate the need for animal model assessment of new drugs, and ultimately more effectively translate new scientific discoveries into safe and effective treatments" commented the Academy's Scientific Director, Dr. Brooke Grindlinger. "Progress in this challenging area is essential if we are to improve our ability to move from discoveries in basic science to clinical application and meet the healthcare challenges of the 21st Ce
|Contact: Brooke Grindlinger|
New York Academy of Sciences